Clinical Report: Investigating HPA Axis Function in Women Undergoing Chemotherapy

Overview

This pilot study evaluated the impact of high-dose dexamethasone on HPA axis function in women with breast cancer undergoing chemotherapy. Results indicated a downward trend in morning cortisol and ACTH levels, but no statistically significant suppression was observed.

Background

Glucocorticoid-induced adrenal insufficiency (GIAI) is a significant risk associated with glucocorticoid therapy, particularly in oncology settings. The use of high-dose dexamethasone during chemotherapy raises concerns about HPA axis suppression, which can lead to life-threatening adrenal crises if unrecognized. Understanding the effects of intermittent high-dose glucocorticoids on adrenal function is crucial for patient safety and management.

Data Highlights

No statistically significant changes in morning cortisol or ACTH concentrations were observed during treatment.

Key Findings

• Morning cortisol and ACTH concentrations showed an overall downward tendency during treatment.
• No significant suppression of morning cortisol or ACTH concentrations was demonstrated during intermittent high-dose dexamethasone administration.
• Single cortisol measurements may not adequately assess adrenal function in oncology patients.
• Further studies are needed to determine optimal methods for evaluating HPA axis function during glucocorticoid exposure.
• Symptoms of adrenal insufficiency can mimic common chemotherapy side effects, complicating diagnosis.

Clinical Implications

Healthcare professionals should be aware of the potential for adrenal insufficiency in patients receiving high-dose dexamethasone during chemotherapy. A longitudinal approach to assessing HPA axis function may be necessary to ensure timely diagnosis and management of adrenal insufficiency.

Conclusion

The study highlights the need for further research into the effects of glucocorticoids on adrenal function in cancer patients. Improved understanding and monitoring strategies are essential for patient safety.

References

1. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Evaluating the Diagnostic Value of Dehydroepiandrosterone Sulfate and Initial Cortisol Levels in Adrenal Insufficiency Assessment
2. The ASCO Post, 2022 -- Expert Point of View: Anne Blaes, MD, MS, and Virginia Kaklamani, MD
3. The ASCO Post, 2022 -- RxPONDER Update Explores Benefit of Chemotherapy in Subgroups
4. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Cortisol Secretion's Impact on Pheochromocytomas and Paragangliomas: Clinical and Perioperative Considerations
5. Endocrine Society, 2024 -- Endocrine Society and European Society of Endocrinology publish joint guideline on glucocorticoid-induced adrenal insufficiency
6. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents - PMC
7. Endocrine Society and European Society of Endocrinology publish joint guideline on glucocorticoid-induced adrenal insufficiency | Endocrine Society
8. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents - PMC
9. Brief Report